GlassScriptPhysician profile
Sami B Nazzal
NPI 1053385575
$12,321.78
in general payments reported to CMS, 2019-2025
36 companies · $785 in 2025
The $785 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,041 · 2020: $119 · 2021: $303 · 2022: $519 · 2023: $1,054 · 2024: $499 · 2025: $785.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,252 · Education: $86.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,252.37 |
| Education | $86.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $6,648.50 | 2019-2023 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $1,823.70 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $513.15 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $407.62 | 2022-2025 | Verquvo, Capvaxive |
| Astrazeneca Pharmaceuticals LP | $364.43 | 2019-2023 | Brilinta, Farxiga, Wainua |
| Abbott Laboratories | $230.12 | 2020-2025 | Diamondback Coronary, Xience Skypoint, Coroflow |
| Amgen INC. | $228.50 | 2019-2025 | Repatha, Repatha |
| Abiomed | $184.66 | 2022-2023 | Impella |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $178.33 | 2022-2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $171.15 | 2019-2025 | Jardiance |
| Scpharmaceuticals INC. | $157.68 | 2023-2024 | |
| Boston Scientific Corporation | $135.13 | 2023-2025 | Watchman Flx |
| Novo Nordisk INC | $120.64 | 2021-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $116.20 | 2022-2025 | |
| Lexicon Pharmaceuticals, INC. | $113.07 | 2023-2024 | Inpefa |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $91.56 | 2025 | Camzyos, Eliquis |
| Cardiovascular Systems INC. | $77.27 | 2019 | |
| Esperion Therapeutics, INC. | $73.60 | 2021-2023 | Nexletol |
| Cvrx, INC. | $66.69 | 2022-2024 | Barostim Neo System |
| Penumbra, INC. | $64.91 | 2022-2023 | Indigo System |
| Gilead Sciences, INC. | $64.60 | 2019 | |
| Terumo Medical Corporation | $64.43 | 2019-2023 | Glidesheath Slender |
| Atricure, INC. | $61.88 | 2023-2025 | Atriclip Laa Exclusion System |
| Sanofi-Aventis U.S. LLC | $55.92 | 2019 | |
| Philips North America LLC | $51.11 | 2020-2024 | (5091) Amb Mon & Diag Und |
| Cardiva Medical, INC. | $48.01 | 2025 | Optowire, Cardiva Vascade Mvp Vvcs 6-12f |
| Heartflow, INC. | $38.91 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $38.80 | 2023 | Arcalyst |
| Kiniksa Pharmaceuticals International, Plc | $26.30 | 2024 | Arcalyst |
| Ge Healthcare | $19.17 | 2023 | |
| W. L. Gore & Associates, INC. | $18.70 | 2020 | |
| Cleerly, INC. | $18.08 | 2025 | Cleerly Ischemia, Cleerly Labs |
| Glaxosmithkline, LLC. | $17.45 | 2025 | Shingrix, Arexvy |
| Amarin Pharma, INC. | $17.41 | 2019 | |
| Chiesi USA, INC. | $13.27 | 2019 | |
| Travere Therapeutics, INC. | $0.83 | 2023 | Cholbam |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sami Nazzal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.